Journal
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 36, Issue 2, Pages 213-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2010.02.001
Keywords
Rheumatoid arthritis; Preclinical period; Anticyclic citrullinated peptide antibodies
Categories
Funding
- NIAMS NIH HHS [L30 AR050481-02, K23 AR051461-05, K23 AR051461-04, L30 AR050481, K23 AR051461-03, K23 AR051461-01, L30 AR050481-01, K23 AR051461-02, K23 AR051461] Funding Source: Medline
Ask authors/readers for more resources
Rheumatoid arthritis (RA) likely develops in several phases, beginning with genetic risk, followed by asymptomatic autoimmunity, then finally, clinically apparent disease. Investigating the phases of disease that exist prior to the onset of symptoms (ie, the preclinical period of RA) will lead to understanding of the important relationships between genetic and environmental factors that may lead to disease, as well as allow for the development of predictive models for disease, and ultimately preventive strategies for RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available